JSI 347d ago

As countries continue to make important decisions regarding dosing strategies for the introduction of new HPV vaccines and initiatives aimed at improving coverage, it is essential to understand the key factors that drive the adoption of a single-dose strategy. In response to this need, our HAPPI Consortium partner, the International Vaccine Access Center (IVAC) at Johns Hopkins Bloomberg School of Public Health conducted key informant interviews across 19 low- and middle-income countries. These interviews helped identify the key factors perceived to influence the adoption of a single-dose strategy. In this webinar we share the results of our research, offering insights into the critical factors that can shape policy dialogues in other countries regarding HPV immunization dosing schedules. You can learn how these findings can inform policy discussions and support the successful implementation of HPV immunization programs worldwide.